title: Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease.
abstract: Studies on the immunotherapy for Alzheimer's disease (AD) have increasingly gained attention since 1990s. However, there are pros (preventing of AD) and cons (incurred cost and side effects) regarding the administration of immunotherapy. Up to date, there has been lacking of economic evaluation for immunotherapy of AD. We aimed to assess the cost-effectiveness analysis of the vaccination for AD.
  
  
  
  A meta-analysis of randomized control trials after systemic review was conducted to evaluate the efficacy of the vaccine. A Markov decision model was constructed and applied to a 120,000-Taiwanese cohort aged ≥65 years. Person years and quality-adjusted life years (QALY) were computed between the vaccinated group and the the unvaccinated group. Economic evaluation was performed to calculate the incremental cost-effectiveness ratio (ICER) and cost-effectiveness acceptability curve (CEAC).
  
  
  
  Vaccinated group gained an additional 0.84 life years and 0.56 QALYs over 10-years and an additional 0.35 life years and 0.282 QALYs over 5-years of follow-up. The vaccinated group dominated the unvaccinated group by ICER over 5-years of follow-up. The ICERs of 10-year follow-up for the vaccinated group against the unvaccinated group were $13,850 per QALY and $9,038 per life year gained. Given the threshold of $20,000 of willingness to pay (WTP), the CEAC showed the probability of being cost-effective for vaccination with QALY was 70.7% and 92% for life years gained after 10-years of follow-up. The corresponding figures were 87.3% for QALY and 93.5% for life years gained over 5-years follow-up.
  
  
  
  The vaccination for AD was cost-effective in gaining QALY and life years compared with no vaccination, under the condition of a reasonable threshold of WTP.
authors.forename: Kuen-Cheh
authors.initials: KC
authors.lastname: Yang
authors.affiliation: Division of Biostatistics, Graduate Institute of Epidemiology and Preventive, Medicine, College of Public Health, National Taiwan University, Room 533, No. 17 Hsuchow Road, Taipei 100, Taiwan. chenlin@ntu.edu.tw.
authors.forename: Hsiu-Hsi
authors.initials: HH
authors.lastname: Chen
mesh_terms: D000544:Alzheimer Disease / Q000191:economics / Q000276:immunology / Q000628:therapy; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D006801:Humans; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic; D014611:Vaccination / Q000379:methods*
references.citation: J Nutr Health Aging. 2010 Oct;14(8):648-54
references.pmid: 20922341
references.citation: Neuron. 2003 May 22;38(4):547-54
references.pmid: 12765607
references.citation: Lancet. 2011 Mar 19;377(9770):1019-31
references.pmid: 21371747
references.citation: Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):198-203
references.pmid: 20505438
references.citation: Am J Psychiatry. 1984 Nov;141(11):1356-64
references.pmid: 6496779
references.citation: J Alzheimers Dis. 2011;24(3):599-607
references.pmid: 21297268
references.citation: N Engl J Med. 2014 Jan 23;370(4):322-33
references.pmid: 24450891
references.citation: Mol Neurodegener. 2013 Oct 22;8:36
references.pmid: 24148220
references.citation: Neurology. 2005 May 10;64(9):1563-72
references.pmid: 15883317
references.citation: Neurology. 2005 May 10;64(9):1553-62
references.pmid: 15883316
references.citation: Curr Alzheimer Res. 2010 Jun;7(4):358-67
references.pmid: 19939223
references.citation: J Psychiatr Res. 1975 Nov;12(3):189-98
references.pmid: 1202204
references.citation: Curr Alzheimer Res. 2013 Feb;10(2):207-16
references.pmid: 23036018
references.citation: Stat Med. 2003 Feb 15;22(3):353-62
references.pmid: 12529868
references.citation: Arch Gerontol Geriatr. 2010 May-Jun;50(3):295-9
references.pmid: 19481822
references.citation: Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S22-32
references.pmid: 9236949
references.citation: J Alzheimers Dis. 2009;16(2):399-407
references.pmid: 19221429
references.citation: J Neurol Neurosurg Psychiatry. 2004 Oct;75(10):1472-4
references.pmid: 15377700
references.citation: Neurobiol Aging. 2009 Nov;30(11):1728-36
references.pmid: 18294736
references.citation: Vaccine. 2008 Nov 18;26(49):6258-65
references.pmid: 18835313
references.citation: Int J Geriatr Psychiatry. 2008 Jan;23(1):73-8
references.pmid: 17520661
references.citation: Alzheimers Dement. 2011 Mar;7(2):208-44
references.pmid: 21414557
references.citation: Pharmacoeconomics. 2010;28(5):411-27
references.pmid: 20402542
references.citation: Clin Ther. 1999 Jul;21(7):1230-40
references.pmid: 10463520
references.citation: Drugs. 2012 Apr 16;72(6):789-802
references.pmid: 22480339
references.citation: Clin Neuropharmacol. 2010 Mar-Apr;33(2):67-73
references.pmid: 20375655
references.citation: Neurology. 2010 Jun 15;74(24):2026; author reply 2026-7
references.pmid: 20548049
references.citation: Curr Alzheimer Res. 2014;11(7):623-5
references.pmid: 25156573
references.citation: Expert Opin Pharmacother. 2011 Feb;12(3):335-50
references.pmid: 21222549
references.citation: Alzheimers Dement. 2012 May;8(3):234-6
references.pmid: 22546355
references.citation: Neurology. 2003 Jul 8;61(1):46-54
references.pmid: 12847155
references.citation: Eur J Health Econ. 2006 Jun;7(2):137-44
references.pmid: 16670912
references.citation: J Intern Med. 2011 Jan;269(1):54-63
references.pmid: 21158978
references.citation: CNS Drugs. 2011 Mar;25(3):213-26
references.pmid: 21323393
references.citation: Curr Alzheimer Res. 2012 Oct;9(8):902-12
references.pmid: 22742853
references.citation: Int J Geriatr Psychiatry. 2004 Mar;19(3):266-70
references.pmid: 15027042
references.citation: Ann Intern Med. 2004 Apr 6;140(7):501-9
references.pmid: 15068977
references.citation: Neurology. 1999 Apr 12;52(6):1138-45
references.pmid: 10214734
references.citation: Int Psychogeriatr. 1997;9 Suppl 1:163-5
references.pmid: 9447439
references.citation: J Geriatr Psychiatry Neurol. 2002 Spring;15(1):16-9
references.pmid: 11936238
references.citation: Neurology. 2001 Sep 25;57(6):957-64
references.pmid: 11571317
references.citation: Neurology. 2008 Nov 4;71(19):1489-95
references.pmid: 18981370
references.citation: Lancet Neurol. 2010 Jan;9(1):119-28
references.pmid: 20083042
references.citation: Can J Psychiatry. 2007 Aug;52(8):519-26
references.pmid: 17955915
references.citation: Lancet. 2005 Dec 17;366(9503):2112-7
references.pmid: 16360788
references.citation: J Geriatr Psychiatry Neurol. 2007 Sep;20(3):172-7
references.pmid: 17712101
references.citation: Curr Alzheimer Res. 2009 Apr;6(2):144-51
references.pmid: 19355849
references.citation: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190
references.pmid: 16437430
references.citation: J Nutr Health Aging. 2009 Mar;13(3):264-7
references.pmid: 19262965
references.citation: Clin Drug Investig. 2004;24(7):373-84
references.pmid: 17516724
references.citation: J Neurochem. 2012 Jan;120 Suppl 1:186-193
references.pmid: 21883222
references.citation: Curr Alzheimer Res. 2012 Dec;9(10):1126-34
references.pmid: 22631442
references.citation: N Engl J Med. 2012 Mar 8;366(10):893-903
references.pmid: 22397651
references.citation: Lancet. 2008 Jul 19;372(9634):216-23
references.pmid: 18640458
references.citation: Neurology. 2005 Jan 11;64(1):94-101
references.pmid: 15642910